OncoMatch/Clinical Trials/NCT06533332
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Is NCT06533332 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ERX-315 for advanced solid tumor.
Treatment: ERX-315 — This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Ovarian Cancer
Endometrial Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Systemic anti cancer therapy within 4 weeks of first dose of study drug
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate baseline organ function
Liver function
adequate baseline organ function
Adequate baseline organ function and hematologic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify